Suppr超能文献

硫利达嗪及其代谢产物在大鼠急性和慢性治疗后血浆和脑中的药代动力学。

Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.

作者信息

Daniel W A, Syrek M, Mach A, Wójcikowski J, Boksa J

机构信息

Department of Pharmacokinetics and Drug Metabolism, Polish Academy of Sciences, Kraków, Poland.

出版信息

Pol J Pharmacol. 1997 Nov-Dec;49(6):439-52.

PMID:9566048
Abstract

This study was aimed at investigation of the pharmacokinetics of thioridazine and its metabolites after a single and repeated administrations. Male Wistar rats received thioridazine as a single dose (10 mg/kg i.p.) or they were treated chronically with the neuroleptic (10 mg/kg i.p., twice a day for two weeks). Plasma and brain concentrations of thioridazine and its metabolites (N-desmethylthioridazine, mesoridazine, sulforidazine, and the ring sulfoxide) were determined using the HPLC method. The obtained data showed that sulfoxidation in position 2 of the thiomethyl substituent and in the thiazine ring are main metabolic pathways of thioridazine, and showed that, in contrast to humans, in the rat N-desmethylthioridazine is formed in appreciable amount. The biotransformation of thioridazine was rather fast yielding plasma peak concentrations of metabolites lower than that of the parent compound. The maximum concentrations of thioridazine and its metabolites in the brain appeared later than in plasma. The peak concentrations and AUC values of thioridazine and its metabolites were higher in the brain than in plasma and this corresponded well with their longer half-lives in the brain as compared to plasma. The drug was not taken up by the brain as efficiently as other phenothiazines. Chronic treatment with thioridazine produced significant increases (with the exception of thioridazine ring sulfoxide) in the plasma concentrations of the parent compound and its metabolites which was accompanied with the prolongation of their plasma half-lives. The observed plasma levels of thioridazine were within 'therapeutic range' while the concentrations of its metabolites were relatively lower as compared to those observed in psychiatric patients. The increased plasma concentrations of thioridazine and its metabolites observed in plasma after chronic treatment were not followed by parallel changes in the brain.

摘要

本研究旨在考察硫利达嗪及其代谢产物在单次及重复给药后的药代动力学。雄性Wistar大鼠接受硫利达嗪单次给药(腹腔注射10mg/kg),或长期接受该抗精神病药物治疗(腹腔注射10mg/kg,每日两次,持续两周)。采用高效液相色谱法测定血浆和脑组织中硫利达嗪及其代谢产物(N-去甲基硫利达嗪、美索达嗪、舒必利嗪和环亚砜)的浓度。所得数据表明,硫甲基取代基2位和噻嗪环的亚砜化是硫利达嗪的主要代谢途径,并且表明,与人类不同,在大鼠体内可形成相当数量的N-去甲基硫利达嗪。硫利达嗪的生物转化相当迅速,代谢产物的血浆峰浓度低于母体化合物。硫利达嗪及其代谢产物在脑组织中的最高浓度出现时间晚于血浆。硫利达嗪及其代谢产物在脑组织中的峰浓度和AUC值高于血浆,这与其在脑组织中的半衰期比血浆中长相一致。该药物在脑组织中的摄取效率不如其他吩噻嗪类药物。长期给予硫利达嗪导致母体化合物及其代谢产物的血浆浓度显著升高(硫利达嗪环亚砜除外),同时其血浆半衰期延长。观察到的硫利达嗪血浆水平在“治疗范围内”,而其代谢产物的浓度与精神病患者相比相对较低。长期治疗后血浆中硫利达嗪及其代谢产物浓度升高,但脑组织中并未出现相应的平行变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验